Hypertension and dyslipidemia. Parallel risk factor control: role of fixed combination
https://doi.org/10.18705/1607-419X-2021-27-3-376-383
Abstract
The combined effect of dyslipidemia and high blood pressure largely contributes to the development and progression of cardiovascular diseases, and therefore the control of these risk factors should be a priority strategy both within primary and secondary prevention. A concept of a polypill, which provides effective control of both blood pressure and lipid profile, is a promising strategy. It allows of controlling several factors of the cardiovascular continuum, and contributes to a higher patient adherence to treatment. Therefore, the wider implementation of a polypill strategy will improve patients’ prognosis and quality of life.
Supporting agencies: The paper is supported by KRKA (Slovenia).
About the Authors
A. O. Konradi
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Aleksandra O. Konradi, MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director General for Research, Head, Hypertension Research Department, Head, Public Healthcare Department, Medical Education Institute, Almazov National Medical Research Centre
St Petersburg
A. S. Alieva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Asiiat S. Alieva, MD, PhD, Head, Laboratory of Lipid Disorders and Atherosclerosis, WCRC for Personalized Medicine, Head, Centre of Atherosclerosis and Lipid Disorders, Almazov National Medical Research Centre
2 Akkuratov street, St Petersburg, 197341
References
1. Metelskaya VA, Shalnova SA, Deev AD, Perova NV, Gomyranova NV, Litinskaya OA et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina = Preventive Medicine. 2016;19(1):15–23. doi:10.17116/profmed201619115–23. In Russian.
2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32): 2459–2472. doi:10.1093/eurheartj/ehx144
3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
4. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020; zwaa047. doi:10.1093/eurjpc/zwaa047
5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
6. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999– 3058. doi:10.1093/eurheartj/ehw272
7. Shalnova SA, Oganov RG, Deev AD, Imaeva AE, Lukyanov ММ, Artamonova GV et al. Comorbidities of ischemic heart disease with other non-communicable diseases in adult population: age and risk factors association. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2015;14(4):44–51. doi:10.15829/1728-8800-2015-4-44-51. In Russian.
8. Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ESSE-RF. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2014;13(6):4–11. doi:10.15829/1728-8800-2014-6-4-11 In Russian.
9. Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. by the data from ESSE. Cardiovascular therapy and prevention. 2014;13(4):4–14. doi:10.15829/1728-8800-2014-4-4-14. In Russian.
10. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484–491.
11. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786 In Russian.
12. 2018 ESC/ESH clinical practice guidelines for the management of arterial hypertension. Eur Heart J. 2019;39(33):3021– 3104. doi:10.1093/eurheartj/ehy339
13. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in highrisk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–145.
14. Ferrari R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensinconverting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166(6):659– 666. doi:10.1001/archinte.166.6.659
15. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788. doi:10.1016/s0140–6736(03)14286–9
16. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–2345. doi:10.1093/eurheartj/ehl250
17. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of hypertension in patients 80 years of age or older. New Engl J Med. 2008;358(18):1887–1898. doi:10.1056/NEJMoa0801369
18. Izzo JL, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am. 2004;88(5):1257–1271. doi:10.1016/j.mcna.2004.06.002
19. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–1158. doi:10.1016/S0140-6736(03)12948-0
20. Schuster H, Fox J. Investigating cardiovascular risk reduction — the Rosuvastatin GALAXY Programme. Exp Opin. 2004;5(5):1187–1200.
21. Susekov AV. Clinical studies of rosuvastatin from the GALAXY project in the context of the new EAS/ ESC-2016 recommendations on dyslipidemia. Part 1. Consilium Medicum. 2017;19(12):12–19. doi:10.26442/2075-1753_19.12.12-19. In Russian.
22. Al Sifri SN, Almahmeed W, Azar S, Okkeh O, Bramlage P, Jünger C et al. Results of the Dyslipidemia International Study (DYSIS) — Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One. 2014;9(1): e84350. doi:10.1371/journal.pone.0084350
23. Gitt AK, Lautsch D, Ferrières J, De Ferrari GM, Vyas A, Baxter CA et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis. 2017;266:158–166. doi:10.1016/j.atherosclerosis.2017.08.013
24. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J et al. Blood pressure and cholesterol lowering in persons without cardiovascular disease. New Engl J Med. 2016;374(21):2032–2043. doi:10.1056/NEJMoa1600177
25. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665–2712.
26. Drapkina OM, Lishuta AS. Using a combination of perindopril, indapamide and rosuvastatin in the treatment of patients with hypertension and dyslipidemia. Rational Pharmacotherapy in Cardiology. 2017;13(4):454–462. doi:10.20996/1819-6446-2017-13-4-454-462 In Russian.
27. Spannella F, Filipponi A, Giulietti F, Di Pentima C, Bordoni V, Sarzani R et al. Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis. J Hypertens. 2020;38(3):546–552. doi:10.1097/HJH.0000000000002276
28. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A et al. Effectiveness of fixed dose combination medication (“polypills”) compared with usual care in patients with cardiovascular disease or at high risk: a prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol. 2016;205:147–156. doi:10.1016/j.ijcard.2015.12.015
29. Thom S, Poulter M, Field J, Patel A, Prabhakaran D, Stanton A et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. J Am Med Assoc. 2013;310(9):918–929.
30. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Br Med J. 2014;348:g3318. doi:10.1136/bmj.g3318
31. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920– 930. doi:10.1177/2047487314530382
Review
For citations:
Konradi A.O., Alieva A.S. Hypertension and dyslipidemia. Parallel risk factor control: role of fixed combination. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(3):376-383. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-3-376-383
Views:
1422
Email this article 